“The second quarter of 2025 was a pivotal period for KALA, marked by the completion of patient enrollment in our Phase 2b CHASE trial of KPI-012 in PCED and the continued execution of our clinical and corporate strategy,” said Todd Bazemore, interim Chief Executive Officer of KALA BIO. “We are well-positioned heading into our key readout of the CHASE trial, which we believe has the potential to serve as a pivotal trial required to support a Biologics License Application to the U.S. Food and Drug Administration, contingent on positive results and subject to discussions with regulatory authorities. We are now focused on finalizing study activities and remain on track to report topline results at the end of September of this year.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALA:
- Kala Pharmaceuticals initiated with a Buy at Ladenburg
- Promising Developments and Market Potential for Kala Pharmaceuticals’ KPI-012 Amidst Clinical and Regulatory Challenges
- Kala Pharmaceuticals Completes Enrollment for Phase 2b Trial
- Kala completes patient enrollment for CHASE Phase 2 clinical trial